Better knowledge of these cardiac effects will contribute to both primary and secondary
prevention of late complications where exposure to cardiotoxic treatment is unavoidable.
Also surrogate markers would help to identify patients at increased risk of cardiotoxicity.
Evidence-based screening guidelines for CVD following cancer are also needed. Finally, risk
prediction models should be developed to guide primary treatment choice and appropriate
follow up after cancer treatment